The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Everolimus is an oral agent that targets the mammalian target of rapamycin (mTOR) pathway. This study investigated mTOR pathway activation in T-cell lymphoma (TCL) cell lines and assessed antitumor activity in patients with relapsed/refractory TCL in a phase 2 trial. The mTOR pathway was activated i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Witzig, Thomas E., Reeder, Craig, Han, Jing Jing, LaPlant, Betsy, Stenson, Mary, Tun, Han W., Macon, William, Ansell, Stephen M., Habermann, Thomas M., Inwards, David J., Micallef, Ivana N., Johnston, Patrick B., Porrata, Luis F., Colgan, Joseph P., Markovic, Svetomir, Nowakowski, Grzegorz S., Gupta, Mamta
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2015
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4504947/
https://ncbi.nlm.nih.gov/pubmed/25921059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-02-629543
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky